RVNC Revance Therapeutics

Watchlist

Close Apr 26 16:00 ET

Post 16:20 ET

354.33MMarket Cap-887P/E (TTM)

Revance Therapeutics Stock Analyst Ratings & Price Target

Updated: Mar 31, 2024

Based on 10 analysts giving stock ratings to Revance Therapeutics in the past 3 months

Buy

Updated: Mar 31, 2024

The average Revance Therapeutics stock price target is 15.80 with a max estimate of 30.00 and a min estimate of 9.00

Review Revance Therapeutics earnings estimates

Receive timely notifications of rating changes

View more detailed ratings of institutions and analysts

View rating details page for historical data

Download APP

Analyst Ratings Disclaimer

Updated: Mar 31, 2024

Buy

Updated: Mar 31, 2024

Overall